Even though there is mounting evidence of the clinical efficacy of SGLT2 inhibitors in HF, a comprehensive understanding of the pathophysiology underlying the cardioprotection of SGLT2 inhibitors is still lacking, also given that SGLT2 is not expressed in cardiomyocytes [120]. This evidence concerns the gene SLC5A2 and hydrops fetalis.